VBI Vaccines – About the Company


Vaccinex is a privately-held, clinical-stage biotechnology company developing immunomodulating antibodies targeting cancer and neurological indications. Vaccinex has completed a Phase I trial in advanced solid tumors for lead product candidate VX15, and is currently conducting a Phase I trial in multiple sclerosis. The antibody targets an important regulator of cell migration and tissue repair and has the potential to be an important complement to current treatments.